tbuckley/cabot-search huggingface dataset:
Hormone Therapy and the Brain
Authors: Kristine Yaffe
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cotton Dust and Lung Disease
Authors: J.E. DIEM
Journal: Annals of Internal Medicine (1983)

Letters and Corrections1 March 1983Cotton Dust and Lung DiseaseJ.E. DIEM, PH.D., R.N. JONES, M.D.J.E. DIEM, PH.D.Search for more papers by this author, R.N. JONES, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-98-3-410_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: The report by Beck and colleagues (1) does not mention a major problem in their study of active and retired cotton textile workers. In the original study (2), the initial target population was 551 card or weave room employees, of whom 377 were assumed to be still alive. Only 152 of the 377 employees were studied. The investigators then added 540 subjects to their study by relaxing their criteria to include other job categories and less stringent dates of employment. Unfortunately, the authors of the original report could no longer define the total population and ". ....References1. BECK G, SCHACHTER E, MAUNDER L, and SCHILLING R. A prospective study of chronic lung disease in cotton textile workers. Ann Intern Med. 1982;97:645-51. LinkGoogle Scholar2. BOUHUYS A, SCHOENBERG J, BECK G, and SCHILLING R. Epidemiology of chronic lung disease in a cotton mill community. Lung. 1977;154:167-86. CrossrefMedlineGoogle Scholar3. MITCHELL C, SCHILLING R, and BOUHUYS A. Community studies of lung disease in Connecticut: organization and methods. Am J Epidemiol. 1976;103:212-25. CrossrefMedlineGoogle Scholar1. BOUHUYS A, SCHOENBERG J, BECK G, and SCHILLING R. Epidemiology of chronic lung disease in a cotton mill community. Lung. 1977;154:167-86. CrossrefMedlineGoogle Scholar2. BOUHUYS A, BECK G, and SCHOENBERG J. Epidemiology of environmental lung disease. Yale J Bio Med. 1979;52:191-210. MedlineGoogle Scholar3. BECK G, SCHACHTER E, MAUNDER L, and SCHILLING R. A prospective study of chronic lung disease in cotton textile workers. Ann Intern Med. 1982;97:645-51. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: J.E. DIEM, PH.D.; R.N. JONES, M.D.Affiliations: Tulane University School of Medicine New Orleans, LA 70112 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 March 1983Volume 98, Issue 3Page: 410-410KeywordsDustLungs ePublished: 1 December 2008 Issue Published: 1 March 1983 PDF downloadLoading ...
Needle Aspiration Biopsy: A Critical Appraisal
Authors: Tilde S. Kline
Journal: JAMA (1978)

Fine-needle aspiration biopsy was used to diagnose lesions from the breast, subcutaneous nodules and lymph nodes, prostate, deep masses, lung, and pancreas. Over an eight-year period, 3,267 specimens were examined. The biopsy specimens were taken with 18- to 22-gauge disposable needles with attached syringes, were fixed immediately, and were stained according to the method of Papanicolaou. Frequently, the aspiration was done as an office procedure. The method was essentially complication-free. The biopsy specimen was easy to interpret, and the procedure had an overall accuracy of approximately 90%. It should be used by all clinicians, especially on the initial visit of the patient.
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
Authors: A Tefferi, E Rumi, G Finazzi, H Gisslinger, A M Vannucchi, F Rodeghiero, M L Randi, R Vaidya, M Cazzola, A Rambaldi, B Gisslinger, L Pieri, M Ruggeri, I Bertozzi, N H Sulai, I Casetti, A Carobbio, G Jeryczynski, D R Larson, L Müllauer, A Pardanani, J Thiele, F Passamonti, T Barbui
Journal: Leukemia (2013)

Under the auspices of an International Working Group, seven centers submitted diagnostic and follow-up information on 1545 patients with World Health Organization-defined polycythemia vera (PV). At diagnosis, median age was 61 years (51% females); thrombocytosis and venous thrombosis were more frequent in women and arterial thrombosis and abnormal karyotype in men. Considering patients from the center with the most mature follow-up information (n=337 with 44% of patients followed to death), median survival (14.1 years) was significantly worse than that of the age- and sex-matched US population (P<0.001). In multivariable analysis, survival for the entire study cohort (n=1545) was adversely affected by older age, leukocytosis, venous thrombosis and abnormal karyotype; a prognostic model that included the first three parameters delineated risk groups with median survivals of 10.9–27.8 years (hazard ratio (HR), 10.7; 95% confidence interval (CI): 7.7–15.0). Pruritus was identified as a favorable risk factor for survival. Cumulative hazard of leukemic transformation, with death as a competing risk, was 2.3% at 10 years and 5.5% at 15 years; risk factors included older age, abnormal karyotype and leukocytes ⩾15 × 109/l. Leukemic transformation was associated with treatment exposure to pipobroman or P32/chlorambucil. We found no association between leukemic transformation and hydroxyurea or busulfan use.
Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer
Authors: Yufei Wang, James D McKay, Thorunn Rafnar, Zhaoming Wang, Maria N Timofeeva, Peter Broderick, Xuchen Zong, Marina Laplana, Yongyue Wei, Younghun Han, Amy Lloyd, Manon Delahaye-Sourdeix, Daniel Chubb, Valerie Gaborieau, William Wheeler, Nilanjan Chatterjee, Gudmar Thorleifsson, Patrick Sulem, Geoffrey Liu, Rudolf Kaaks, Marc Henrion, Ben Kinnersley, Maxime Vallée, Florence Le Calvez-Kelm, Victoria L Stevens, Susan M Gapstur, Wei V Chen, David Zaridze, Neonilia Szeszenia-Dabrowska, Jolanta Lissowska, Peter Rudnai, Eleonora Fabianova, Dana Mates, Vladimir Bencko, Lenka Foretova, Vladimir Janout, Hans E Krokan, Maiken Elvestad Gabrielsen, Frank Skorpen, Lars Vatten, Inger Njølstad, Chu Chen, Gary Goodman, Simone Benhamou, Tonu Vooder, Kristjan Välk, Mari Nelis, Andres Metspalu, Marcin Lener, Jan Lubiński, Mattias Johansson, Paolo Vineis, Antonio Agudo, Francoise Clavel-Chapelon, H Bas Bueno-de-Mesquita, Dimitrios Trichopoulos, Kay-Tee Khaw, Mikael Johansson, Elisabete Weiderpass, Anne Tjønneland, Elio Riboli, Mark Lathrop, Ghislaine Scelo, Demetrius Albanes, Neil E Caporaso, Yuanqing Ye, Jian Gu, Xifeng Wu, Margaret R Spitz, Hendrik Dienemann, Albert Rosenberger, Li Su, Athena Matakidou, Timothy Eisen, Kari Stefansson, Angela Risch, Stephen J Chanock, David C Christiani, Rayjean J Hung, Paul Brennan, Maria Teresa Landi, Richard S Houlston, Christopher I Amos
Journal: Nature Genetics (2014)
German Bundestag debates proposed law on assisted suicide
Authors: N. Stafford
Journal: BMJ (2014)

The Bundestag, Germany’s lower house of parliament, has officially opened debate on a planned new law to regulate assisted suicide. Some 48 members of the 631 member body stepped to the podium to express their views during a five hour session.

In opening the floor to the debate on 13 November Norbert Lammert, Bundestag president, described the enactment of an assisted suicide law as “perhaps the most challenging project of this legislative period.” And in addition to the initial Bundestag debate five groups of MPs, some crossing party lines, issued position papers outlining their opinions on this highly controversial issue.1 2 3 4 5

A landmark German court ruling in 2010 gave patients the right to refuse medical treatments designed to prolong their life6—described in Germany as passive assisted suicide. But assisting in an “active” suicide is not legally regulated, leaving a grey area for prosecutorial interpretation that proponents …
Anticancer Drugs Reduce Type 1 Diabetes Incidence in Mice
Authors: Tracy Hampton
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
P4-08-05: Diagnostic Significance of Exosomal miRNAs in the Plasma of Breast Cancer Patients.
Authors: A Kwong, EKO Ng, CPH Leung, V Chan, R Li, CLP Wong, ESK Ma
Journal: Cancer Research (2011)

Abstract Background and Aims: Emerging evidence that microRNAs (miRNAs) play an important role in cancer development has opened up new opportunities for cancer diagnosis. Recent studies demonstrated that released exosomes which contain a subset of both cellular mRNA and miRNA could be a useful source of biomarkers for cancer detection. Here, we aim to develop a novel biomarker for breast cancer diagnosis using exosomal miRNAs in plasma. Methods: We have developed a rapid and novel isolation protocol to enrich tumor-associated exosomes from plasma samples by capturing tumor specific surface markers containing exosomes. After enrichment, we performed miRNA profiling on four sample sets; (1) Ep-CAM marker enriched plasma exosomes of breast cancer patients; (2) breast tumors of the same patients; (3) adjacent non-cancerous tissues of the same patients; (4) Ep-CAM marker enriched plasma exosomes of normal control subjects. Profiling is performed using PCR-based array with human microRNA panels that contain more than 700 miRNAs. Results: Our profiling data showed that 15 miRNAs are concordantly up-regulated and 13 miRNAs are concordantly down-regulated in both plasma exosomes and corresponding tumors. These account for ∼25% (up-regulation) and ∼15% (down-regulation) of all miRNAs detectable in plasma exosomes. Our findings demonstrate that miRNA profile in EpCAM-enriched plasma exosomes from breast cancer patients exhibit certain similar pattern to that in the corresponding tumors. Based on our profiling results, plasma signatures that differentiated breast cancer from control are generated and some of the well-known breast cancer related miRNAs such as miR-10b, miR-21, miR-155 and miR-145 are included in our panel list. The putative miRNA biomarkers are validated on plasma samples from an independent cohort from more than 100 cancer patients. Further validation of the selected markers is likely to offer an accurate, noninvasive and specific diagnostic assay for breast cancer. Conclusions: These results suggest that exosomal miRNAs in plasma may be a novel biomarker for breast cancer diagnosis. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-08-05.
Malignant Melanoma and Epidermolysis Bullosa Simplex
Authors: Jo-David Fine
Journal: JAMA Dermatology (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2022 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
European drug regulator is being investigated by fraud agency
Authors: Z. Kmietowicz
Journal: BMJ (2011)

The agency responsible for regulating drugs across the European Union is being investigated for alleged conflicts of interest by the European Commission’s Anti-Fraud Office.

The European Medicines Agency, which is based in London, confirmed that the office has started an investigation but said that it had received no “further communication with regard to the scope and timeframe of the investigation.”

The investigation was triggered by the scandal over the French antidiabetes drug benfluorex, marketed as Mediator by the French drug company Servier. The …
The Oslo Diet-Heart Study
Authors: PAUL LEREN
Journal: Circulation (1970)

The study deals with 412 men, aged 30 to 64 years, randomized 1 to 2 years after a first myocardial infarction. For the experimental group a diet low in saturated fats and cholesterol, and high in polyunsaturated fats was recommended. After 5 years, as reported previously, the incidence of fatal and nonfatal myocardial reinfarction was found to be significantly reduced. "Sudden death" was uninfluenced. Major coronary heart disease (CHD) relapses, including fatal and nonfatal events (MI), were significantly reduced ( P = 0.05). After 11 years, death from all causes had occurred in 101 of the original dieters and 108 controls. A significantly reduced myocardial infarction mortality in the original diet group was found (32 versus 57, P = 0.004). The total number of coronary deaths (fatal myocardial infarction and sudden death) was 79 in the diet group and 94 in the control group ( P = 0.097). The CHD mortality was correlated with age, serum cholesterol level, blood pressure, body weight, smoking habits, and a combination of these risk factors.
How Do Intellectual Property Law and International Trade Agreements Affect Access to Antiretroviral Therapy?
Authors: Michael Westerhaus, Arachu Castro
Journal: PLoS Medicine (2006)

In recent years, globalization has forced a deeper appreciation of the relationship between intellectual property (IP) law and global health. The threat of an emergent avian bird flu pandemic led to calls for Roche to relax patent restrictions on oseltamivir, a drug with potential efficacy against bird influenza [1,2]. In the context of the fall 2001 anthrax attacks, the US government faced pressure to break Bayer's patent on ciprofloxacin in order to increase availability of the drug [3]. Such situations have generated intense debate over the value of patent protection amidst health crises.

Nowhere have these debates been more intense than around the issue of global access to HIV treatment. Multinational pharmaceutical companies, World Trade Organization (WTO) members, US and European Union trade representatives, and health-care activists have clashed over provision of antiretroviral therapy (ART) to people living with AIDS in developing countries. The debate centers upon the value and role of patents obtained for HIV-related pharmaceutical products, drug-manufacturing techniques, and forms of drug delivery. These arguments have recently intensified amidst an increased US pursuit of bilateral, regional, and multilateral trade agreements—which include strong IP provisions—with low- and middle-income countries throughout the world.

In this paper, we examine the key areas of concern regarding access to ART related to US-negotiated bilateral, regional, and multilateral trade agreements. We first examine developments in IP law in the wake of WTO's Doha Declaration, which affirmed the priority of public health over the protection of patents. We look specifically at those developments with particular salience for health-related issues and link this history with the current context of access to antiretrovirals (ARVs) worldwide. Next we map out the key claims about, and questions surrounding, the role of patent law, followed by a critical look at the impact of trade agreements on IP law and their potential threat to global health. Finally, we suggest policy and advocacy strategies to ensure and promote access to ART in the era of US-led attempts to strengthen global IP law through the vehicle of “free” trade agreements.
Common polymorphisms of the peroxisome proliferator-activated receptor–γ (Pro12Ala) and peroxisome proliferator-activated receptor–γ coactivator–1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus
Authors: Ming-Chia Hsieh, Kun-Der Lin, Kai-Jen Tien, Shih-Te Tu, Jeng-Yueh Hsiao, Shun-Jen Chang, Shiu-Ru Lin, Shih-Jang Shing, Hung-Chun Chen
Journal: Metabolism (2010)
Use of Imipramine in Children with Intractable Asthma and Psychiatric Disorders: A Warning
Authors: Andres M. Kanner, Rachel G. Klein, Boris Rubinstein, Armond Mascia
Journal: Psychotherapy and Psychosomatics (1989)

Imipramine is an established treatment for anxiety in adults. Some evidence also exists that it may be beneficial in children. Because of the frequent co-occurrence of anxiety and affective symptomatology in asthmatic children, a pilot study was undertaken to obtain clinical observations on the effects of imipramine on symptoms of asthma as well as those of separation anxiety and depression in children suffering from intractable asthma. The pilot trial was terminated because of medical complications after 6 patients participated.
In vitro and in vivo anti-biofilm effects of silver nanoparticles immobilized on titanium
Authors: Hui Qin, Huiliang Cao, Yaochao Zhao, Cheng Zhu, Tao Cheng, Qiaojie Wang, Xiaochun Peng, Mengqi Cheng, Jiaxin Wang, Guodong Jin, Yao Jiang, Xianlong Zhang, Xuanyong Liu, Paul K. Chu
Journal: Biomaterials (2014)
Abstract 1310: Increased cytoplasmic CDC25A phosphatase in cutaneous squamous cell carcinoma leads to 14-3-3 relocalization and suppression of apoptosis
Authors: Jenan Almatouq, Kristen Ho, Laura A. Hansen
Journal: Cancer Research (2014)

Abstract Non-melanoma skin cancer, the most common cancer in the United States, frequently results from chronic exposure to ultraviolet (UV) irradiation. UV-induced DNA damage activates cell cycle arrest checkpoints through degradation of the cyclin-dependent kinase activators, the Cell Division Cycle 25 (CDC25) phosphatases, which are over-expressed and, thus, deregulate cell cycle control in many human cancers. To investigate a role for CDC25 in skin cancer, CDC25 levels were examined in both UV-induced mouse tumors and human skin cancer. CDC25A and CDC25C protein and transcripts were increased in benign and malignant skin tumors from UV-exposed v-rasHa transgenic Tg.AC mice. CDC25B protein but not transcripts was increased in mouse skin tumors compared to normal skin. Similarly, CDC25A and CDC25C but not CDC25B were elevated in human squamous cell carcinoma (SCC) and in the premalignant precursors actinic keratosis and Bowen's disease when compared to skin. While CDC25A was localized primarily to nuclei in normal epidermis, both the premalignant precursors and SCC exhibited strong cytoplasmic CDC25A localization. To determine whether increased CDC25A stimulates proliferation in skin SCC, CDC25A levels were modulated by siRNA-targeting or forced expression in cultured SCC cells, but no difference in proliferation resulted. Because cytoplasmic CDC25A can bind to the apoptotic regulator 14-3-3, we hypothesized that the increase in cytoplasmic CDC25A may suppress apoptosis. Forced over-expression of CDC25A in SCC cells suppressed cell death, whereas CDC25A silencing increased apoptotic cell death. Phosphorylation of CDC25A at serine178, a docking site for 14-3-3 proteins, was elevated in the cytoplasmic compartment of SCCs, and cytoplasmic 14-3-3ϵ was increased in cutaneous SCC.Mutation of the nuclear export sequence on CDC25A relocalized both CDC25A and 14-3-3ϵ to the nucleus, while mutation of 14-3-3 binding sites on CDC25A led to a decrease in 14-3-3ϵ levels. Furthermore, silencing of 14-3-3ϵ increased cell death by 60%. Taken together, these data suggest that increased cytoplasmic CDC25A in cutaneous SCC may suppress apoptotic cell death through its interaction with 14-3-3ϵ. Citation Format: Jenan Almatouq, Kristen Ho, Laura A. Hansen. Increased cytoplasmic CDC25A phosphatase in cutaneous squamous cell carcinoma leads to 14-3-3 relocalization and suppression of apoptosis. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1310. doi:10.1158/1538-7445.AM2014-1310
Diffusion Processes Invalidating the Intra-arterial Krypton-85 Beta-Particle Clearance Method for Measurement of Skin Blood Flow in Man
Authors: PER SEJRSEN
Journal: Circulation Research (1967)

Krypton-85 dissolved in 0.9% NaCl was injected into the femoral artery of man; β particles were measured over the skin of the crus. Cutaneous mean blood flow was calculated using the integral equation of Zierler based on the mean transit time analysis of clearance curves recorded from the cutaneous tissue; these calculations gave estimates which were only about one-fifth those obtained by other methods. The low estimates were caused by an intercom-partmental exchange of 85 krypton between the cutaneous and subcutaneous tissues, an exchange implying that both tissues influence the shape of the clearance curve recorded from the cutaneous tissue alone. This intercompart-mental exchange was effected not only by diffusion directly from the cutaneous to the subcutaneous tissue, but presumably also by transport from the blood streaming between the two tissues. The clearance rate of the tail of the curve was shown to correspond to that of the subcutaneous tissue. The errors distorting the clearance curve of β particles may invalidate the use of intra-arterial injection and measurement of clearance curves of β particles for measurement of blood flow in other tissues.